AbbVie News

Aktie
WKN:  A1J84E ISIN:  US00287Y1091 US-Symbol:  ABBV Branche:  Pharmazeutika Land:  USA
219,68 $
-5,69 $
-2,52%
192,42 € 13.03.26
Depot/Watchlist
Marktkapitalisierung *
345,80 Mrd. €
Streubesitz
24,69%
KGV
21,69
Dividende
5,85 EUR
Dividendenrendite
3,03%
Nachhaltigkeits-Score
46 %
Index-Zuordnung
S&P 500
Weiter abwärts? Short handeln - Jetzt mit Hebel 7,69: VG75H6
Werbung

AbbVie News

12.01.26 - PR Newswire
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans
AbbVie and Trump Administration Reach Agreement to Improve Access and Affordability for Americans PR Newswire
12.01.26 - PR Newswire
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors
AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors PR Newswire
12.01.26 - PR Newswire
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States
AbbVie to Acquire Arizona Manufacturing Facility, Further Strengthening Manufacturing Capabilities in the United States PR Newswire
12.01.26 - PR Newswire
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie
West Signs Agreement to Sell the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System to AbbVie PR Newswire
07.01.26 - PR Newswire
AbbVie to Host Full-Year and Fourth-Quarter 2025 Earnings Conference Call
AbbVie to Host Full-Year and Fourth-​Quarter 2025 Earnings Conference Call PR Newswire
06.01.26 - wallstreetONLINE Redaktion
Wachstum, Pipeline, Cash: Diese Pharma-Story überzeugt
Immunologie liefert starkes Wachstum, der Cashflow sprudelt und die Pipeline bringt neue Fantasie. Trotz kräftiger Kurs­gewinne sehen Analysten weiteres Potenzial für diese ...
05.01.26 - PR Newswire
AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference
AbbVie to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
02.12.25 - PR Newswire
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers PR Newswire
01.12.25 - PR Newswire
AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei der Schmerzlinderung in der Akutbehandlung von Migräne belegen
AbbVie präsentiert auf dem 19. European Headache Congress Phase-3-Daten aus der ECLIPSE-​Studie, die die Überlegenheit von Atogepant (AQUIPTA®) gegenüber Placebo bei ...
01.12.25 - LYNX Analysen
AbbVie: Pharmaunternehmen vor möglichem Breakout?
AbbVie zeigt sich in einem stabilen technischen Umfeld und konsolidiert über wichtigen Durchschnittslinien. Könnte ein möglicher Breakout bevorstehen? Jetzt vollständige Analyse ...
01.12.25 - PR Newswire
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th European Headache Congress
AbbVie to Present Phase 3 ECLIPSE Data Demonstrating Atogepant (AQUIPTA®) Superiority Over Placebo in Achieving Pain Freedom for the Acute Treatment of Migraine at the 19th ...
26.11.25 - wallstreetONLINE Redaktion
Trump-Deal erschüttert Pharma: Preissturz bei Top-Medikamenten: Welche Aktien jetzt richtig unter Druck stehen!
Die US-​Regierung setzt einen Preissturz bei Ozempic und Wegovy durch. Patienten zahlen ab 2027 nur noch einen Bruchteil. Hinter dem Deal stehen Interessen, die den Markt ...
24.11.25 - PR Newswire
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference
AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference PR Newswire
18.11.25 - PR Newswire
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma
AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-​bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma PR ...
14.11.25 - PR Newswire
AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
AbbVie Partners with Award-​Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer PR Newswire
13.11.25 - PR Newswire
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™ PR Newswire
12.11.25 - PR Newswire
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence
Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence PR Newswire
31.10.25 - PR Newswire
AbbVie Reports Third-Quarter 2025 Financial Results
AbbVie Reports Third-​Quarter 2025 Financial Results PR Newswire
29.10.25 - wallstreetONLINE Redaktion
Earnings Preview – Teil 2: Nach Fed-Enttäuschung: Am Donnerstag müssen Amazon, Apple und Co. liefern!
Diese in den kommenden Tagen (KW44) anstehenden US-​Quartals­zahlen müssen Anlegerinnen und Anleger kennen: Herausforderungen, Erwartungen und die aktuell ...
29.10.25 - PR Newswire
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year
The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year PR Newswire

Newssuche

Videos

newspaper
13.03.26 -3,08%
Technical Trading: Kurzfristig Gold Long
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »